The Efficacy and Safety of Janus Kinase Inhibitors in Patients with Atopic Dermatitis: A Systematic Review and Meta-analysis

Published: 11 April 2022| Version 2 | DOI: 10.17632/89x8s56p5z.2
Contributors:
,
,
,
Wei Tu,
Yan Zhang,
,
Hua Wang

Description

These data is a supplementary data for a manuscript entitled "The Efficacy and Safety of Janus Kinase Inhibitors in Patients with Atopic Dermatitis: A Systematic Review and Meta-analysis". In this study, we showed that JAK inhibitors are a promising treatment option for AD. Due to the higher risk of gastrointestinal disorders, nasopharyngitis and headache during oral JAKi treatments, more attention should be paid on the adverse effects of patients treated with oral JAKi. Further studies with long follow-up in the different conditions will be needed to fully elucidate the safety profile of the different JAK inhibitors.

Files

Institutions

Chongqing Medical University

Categories

Supplementary Lighting

License